Hexyl aminolevulinate - Photocure
Alternative Names: 5-ALA hexylester; 5-ALA hexylesther; aminolevulinic acid hexyl ester; APL-1702; APL-1706; Cevira; Cysview; HAL-PDT; hexaminolevulinate; Hexvix; Hexvix PDT; hexyl 5-aminolevulinate; P 1206Latest Information Update: 07 Oct 2024
Price :
$50 *
At a glance
- Originator PhotoCure
- Developer Asieris Pharmaceuticals; Genotests; Ipsen; Juno Pharmaceuticals; Photocure
- Class Amino acids; Antineoplastics; Esters; Imaging agents; Levulinic acids; Oxidants; Small molecules
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Bladder cancer
- Preregistration Cervical intraepithelial neoplasia
- Discontinued Colorectal cancer
Most Recent Events
- 07 Oct 2024 Preregistration for Cervical intraepithelial neoplasia in European Union (Topical) (Asieris Pharmaceuticals pipeline, October 2024)
- 30 Sep 2024 Updated efficacy data from phase III APRICITY trial in Cervical intraepithelial neoplasia released by Photocure
- 31 May 2024 National Medical Products Administration (NMPA) accepts NDA for Hexyl aminolevulinate for cervical intraepithelial neoplasia for review in China